AVITA Medical Inc RCEL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $4.02
- Day Range
- $4.02–4.74
- 52-Week Range
- $3.22–7.12
- Bid/Ask
- $4.64 / $4.75
- Shares Outstanding
- 30.78M
- Market Cap
- $145.57M
- Volume/Avg
- 412,540 / 283,552
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.89
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 226
- Website
- https://www.avitamedical.com
Valuation
|
Metric
|
RCEL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1.89 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RCEL
|
|---|---|
Quick Ratio | 0.36 |
Current Ratio | 0.47 |
Interest Coverage | −7.77 |
Quick Ratio
RCEL
Profitability
|
Metric
|
RCEL
|
|---|---|
Return on Assets (Normalized) | −62.42% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −98.96% |
Return on Assets
RCEL
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|<JbhwK | LOCK|$H#m | $155B | |||
| Stryker Corp
SYK
| LOCK|wNjHvPx | LOCK|fg | $121B | |||
| Medtronic PLC
MDT
| LOCK|rWL^dGL | LOCK|%PwMY | $103B | |||
| Boston Scientific Corp
BSX
| LOCK|S&WpnD | LOCK|K>LD | $64B | |||
| Edwards Lifesciences Corp
EW
| LOCK|?dh#J^b^ | LOCK|#&&% | $50B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|%T$Pxk | LOCK|>s | $29B | |||
| DexCom Inc
DXCM
| LOCK|cT$pJM# | LOCK|>Z?k@ | $28B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|RG | LOCK|<w | $25B | |||
| Steris PLC
STE
| LOCK|!XgZ%p | LOCK|zd@$ | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|>#VzhbKN | LOCK|rL | $17B |
United States